Market Overview
The global kidney cancer therapeutics and diagnostics market was valued at USD 5.37 Billion in 2024 and is projected to reach USD 9.24 Billion by 2033, growing at a CAGR of 5.90% during the forecast period of 2025-2033. The growing prevalence of kidney cancer, rising geriatric population, and favorable government initiatives are key drivers. Improved diagnostic technologies and innovative therapies like targeted treatments and immunotherapies support the market expansion.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
Kidney Cancer Therapeutics and Diagnostics Market Key Takeaways
- The kidney cancer therapeutics and diagnostics market was valued at USD 5.37 Billion in 2024.
- The market is expected to grow at a CAGR of 5.90% during 2025-2033.
- The forecast period for market growth is 2025-2033.
- North America dominates the market with over 35.4% share in 2024.
- The United States leads North America with an 89.60% market share.
- Key market growth drivers include the rising incidence of kidney cancer, aging populations, and government awareness initiatives.
Sample Request Link: https://www.imarcgroup.com/kidney-cancer-therapeutics-diagnostics-market/requestsample
Market Growth Factors
The global increase in kidney cancer cases has propelled demand for improved treatment and diagnostics. Factors such as aging populations and lifestyle habits including smoking, obesity, and high blood pressure contribute significantly. For example, in the U.S., kidney cancer resulted in nearly 15,000 deaths in 2023, with over 90 percent cases being renal cell carcinoma. This underscores the need for early diagnosis and innovative therapies to improve survival and treatment outcomes.
Significant advancements in diagnostic technologies, such as biomarker-based diagnostics, liquid biopsies, and advanced imaging like PET/CT scans, have enhanced early detection rates, thereby enabling more effective treatment planning. Therapeutic innovations including targeted therapies, immune checkpoint inhibitors, and personalized medicine approaches have revolutionized kidney cancer treatment, fueling market growth.
Growing investments in research and development, supported by entities like the National Cancer Institute and Department of Defense’s Kidney Cancer Research Program, have accelerated the discovery of novel biomarkers and therapies. For instance, Weill Cornell Medicine received a USD 1 million grant for researching ATF4 protein's function in clear cell renal cell carcinoma, demonstrating continual innovation in this field fostering market expansion.
Market Segmentation
By Component:
- Drugs: Dominating the market with approximately 84.3% share in 2024 due to high efficacy and fewer side effects with targeted therapies and immunotherapies. Notable drugs include TKIs such as sunitinib and pazopanib, and immune checkpoint inhibitors like pembrolizumab and nivolumab.
- Diagnostics: Includes imaging tests, biopsies, blood tests, and others supporting early detection and treatment planning.
By Cancer Types:
- Clear Cell RCC: Leading with around 66.3% market share in 2024, characterized by clear cells rich in lipid and glycogen, often diagnosed late with poor prognosis if untreated promptly.
- Other types include papillary RCC, chromophobe RCC, transitional cell carcinoma.
By Application:
- Hospitals: Holding approximately 40.0% of the market share in 2024, hospitals possess the necessary infrastructure for diagnostics and treatment, including oncology units and multidisciplinary care teams.
- Others include pharmaceutical labs, genomic laboratories.
Regional Insights
North America leads with a 35.4% market share in 2024, driven by the U.S. which controls 89.60% of the regional market. The region benefits from high kidney cancer prevalence, advanced healthcare infrastructure, significant R&D investments, and early detection programs. This combination fosters the development and adoption of targeted therapies and immunotherapies, making North America the largest market for kidney cancer therapeutics and diagnostics.
Recent Developments & News
- September 2023: A global diagnostics company partnered with a major South African firm to promote early kidney cancer diagnosis using liquid biopsy and biomarker testing technologies across African countries.
- August 2023: A multinational pharmaceutical company launched a new immunotherapy drug for renal cell carcinoma (RCC) in the UAE, marking progress in precision therapies in the Middle East.
- June 2023: A leading health technology company installed innovative AI-based imaging technology across the Middle East to enhance kidney cancer diagnosis via deep learning algorithms.
Key Players
- Bristol-Myers Squibb Company
- Exelixis Inc.
- Genentech Inc. (Roche Holding AG)
- Novartis AG
- Pfizer Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
Comments (0)